IP Library Granted Patent US 9,872,839
Granted Patent B2
US 9,872,839 · App. 15/425,528 · Granted Jan 23, 2018

Compositions and methods for diagnosing or treating neutrophil-mediated inflammatory disease

Inventors: Zhenjia Wang (Spokane, WA); Jaehyung Cho (Western Springs, IL); Asrar Malik (Hinsdale, IL)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
A61K31/05A61K9/0019A61K9/1658A61K9/5169A61K31/573G01N33/5005G01N2800/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,872,839
App. No.
15/425,528
Granted
Jan 23, 2018
Kind
B2
Abstract

Disclosed are nanoparticle compositions comprising nanoparticles prepared from denatured, cross-linked albumin and a therapeutic agent for treating a neutrophil-mediated inflammation, and methods of treating neutrophil-mediated inflammation using the compositions.

Claims (14)

1. A method of treating a neutrophil-mediated inflammatory disease in a subject in need of treatment comprising:

administering to the subject a therapeutically effective amount of a composition comprising nanoparticles, each nanoparticle consisting of denatured, cross-linked albumin and a therapeutic agent, the nanoparticles selectively binding to and internalized by activated neutrophils.

2. The method of claim 1 , wherein the therapeutic agent is one or more selected from the group consisting of anti-inflammatory glucocorticoids, NF-kB inhibitors, p38MAP kinase inhibitors, Syk/Zap kinase inhibitors and siRNA oligonucleotides.

3. The method of claim 1 , wherein the therapeutic agent is dexamethasone or piceatannol.

4. The method of claim 1 , wherein the neutrophil-mediated inflammatory disease is selected from the group consisting of sepsis, myocardial infarction, acute lung injury, stroke and ischemia-reperfusion injury.

5. The method of claim 1 , wherein the therapeutic agent is loaded within the nanoparticles or covalently conjugated to the albumin.

6. The method of claim 1 , wherein each of the nanoparticles has a mean particle diameter of about 90 nm to about 110 nm.

7. The method of claim 1 , wherein the nanoparticles are administered intravenously.

8. The method of claim 1 , wherein the subject is a human.

9. The method of claim 1 wherein the denatured albumin is denatured by desolvation.

10. The method of claim 9 wherein the albumin is desolvated by treatment with ethanol.

11. The method of claim 1 wherein the albumin is bovine serum albumin.

12. The method of claim 1 wherein the albumin is cross-linked with glutaraldehyde.

13. A composition comprising nanoparticles, each nanoparticle consisting of denatured, cross-linked albumin and a therapeutic agent, the nanoparticles selectively binding to and internalized by activated neutrophils.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2017
From: WANG, ZHENJIA; CHO, JAEHYUNG; MALIK, ASRAR
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 042526/0877 →
Continuity (3)
Continuation 14316036 · Jun 26, 2014
Provisional Application 61840597 · Jun 28, 2013
Related Publication 20170143645A1 · May 25, 2017